{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:45:25Z","timestamp":1789969525227,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T00:00:00Z","timestamp":1188864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s12016-007-8021-6","type":"journal-article","created":{"date-parts":[[2007,9,3]],"date-time":"2007-09-03T07:41:02Z","timestamp":1188805262000},"page":"56-64","source":"Crossref","is-referenced-by-count":72,"title":["Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders"],"prefix":"10.1007","volume":"34","author":[{"given":"Enno","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Bettina","family":"Br\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,4]]},"reference":[{"key":"8021_CR1","first-page":"113","volume":"16","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Zillikens D (2000) Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 16:113\u2013157","journal-title":"Adv Dermatol"},{"key":"8021_CR2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMra061111","volume":"355","author":"JR Stanley","year":"2006","unstructured":"Stanley JR, Amagai M (2006) Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 355:1800\u20131810","journal-title":"N Engl J Med"},{"key":"8021_CR3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","volume":"149","author":"KE Harman","year":"2003","unstructured":"Harman KE, Albert S, Black MM (2003) Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149:926\u2013937","journal-title":"Br J Dermatol"},{"key":"8021_CR4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1439-0353.2004.04702.x-i1","volume":"2","author":"M Goebeler","year":"2004","unstructured":"Goebeler M, Sitaru C, Zillikens D (2004) Bullous autoimmune disorders: therapy. J Dtsch Dermatol Ges 2:774\u2013793","journal-title":"J Dtsch Dermatol Ges"},{"key":"8021_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/17469872.1.3.401","volume":"1","author":"M Goebeler","year":"2006","unstructured":"Goebeler M, Zillikens D (2006) Bullous pemphigoid: diagnosis and management. Expert Review of Dermatology 1:401\u2013411","journal-title":"Expert Review of Dermatology"},{"key":"8021_CR6","first-page":"811","volume":"88","author":"Y Cohen","year":"2003","unstructured":"Cohen Y, Solal-Celigny P, Polliack A (2003) Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88:811\u2013823","journal-title":"Haematologica"},{"key":"8021_CR7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJM199411033311807","volume":"331","author":"JN George","year":"1994","unstructured":"George JN, el-Harake MA, Raskob GE (1994) Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331:1207\u20131211","journal-title":"N Engl J Med"},{"key":"8021_CR8","first-page":"24","volume":"77","author":"DA Isenberg","year":"2006","unstructured":"Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24\u201328","journal-title":"J Rheumatol Suppl"},{"key":"8021_CR9","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"8021_CR10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564\u2013576","journal-title":"Nat Rev Drug Discov"},{"key":"8021_CR11","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580\u20133590","journal-title":"Arthritis Rheum"},{"key":"8021_CR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613\u2013620","journal-title":"Arthritis Rheum"},{"key":"8021_CR13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.intimp.2004.04.015","volume":"4","author":"Y Vugmeyster","year":"2005","unstructured":"Vugmeyster Y, Howell K (2005) Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol 4:1117\u20131124","journal-title":"Int Immunopharmacol"},{"key":"8021_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","volume":"48","author":"JH Anolik","year":"2003","unstructured":"Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455\u2013459","journal-title":"Arthritis Rheum"},{"key":"8021_CR15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2005.02720.x","volume":"139","author":"E Janas","year":"2005","unstructured":"Janas E, Priest R, Wilde JI, White JH, Malhotra R (2005) Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139:439\u2013446","journal-title":"Clin Exp Immunol"},{"key":"8021_CR16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174\u2013178","journal-title":"Arch Dermatol"},{"key":"8021_CR17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","volume":"115","author":"C Sitaru","year":"2005","unstructured":"Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D (2005) Induction of dermal\u2013epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115:870\u2013878","journal-title":"J Clin Invest"},{"key":"8021_CR18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883\u2013888","journal-title":"Ann Rheum Dis"},{"key":"8021_CR19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","volume":"31","author":"E Schmidt","year":"2006","unstructured":"Schmidt E, Hunzelmann N, Zillikens D, Broecker EB, Goebeler M (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503\u2013508","journal-title":"Clin Exp Dermatol"},{"key":"8021_CR20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","volume":"156","author":"E Schmidt","year":"2007","unstructured":"Schmidt E, Seitz CS, Benoit S, Br\u00f6ecker EB, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352\u2013356","journal-title":"Br J Dermatol"},{"key":"8021_CR21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","volume":"31","author":"AS Belgi","year":"2006","unstructured":"Belgi AS, Azeez M, Hoyle C, Williams RE (2006) Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 31:143","journal-title":"Clin Exp Dermatol"},{"key":"8021_CR22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","volume":"22","author":"HH Kong","year":"2005","unstructured":"Kong HH, Prose NS, Ware RE, Hall RP 3rd (2005) Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 22:461\u2013464","journal-title":"Pediatr Dermatol"},{"key":"8021_CR23","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772\u20131779","journal-title":"N Engl J Med"},{"key":"8021_CR24","first-page":"269","volume":"137","author":"L Borradori","year":"2001","unstructured":"Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A (2001) Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137:269\u2013272","journal-title":"Arch Dermatol"},{"key":"8021_CR25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-3083.2005.01345.x","volume":"20","author":"M Barnadas","year":"2006","unstructured":"Barnadas M, Roe E, Brunet S, Garcia P, Bergua P, Pimentel L, Puig L, Francia A, Garcia R, Gelpi C, Sierra J, Coll P, Alomar A (2006) Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 20:69\u201374","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8021_CR26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555-0007","volume":"86","author":"M Esposito","year":"2006","unstructured":"Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S (2006) Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 86:87\u201389","journal-title":"Acta Derm Venereol"},{"key":"8021_CR27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.revmed.2006.11.012","volume":"28","author":"C Borel","year":"2006","unstructured":"Borel C, Launay F, Garrouste C, Astudillo L, Bazex J, Arlet P, Paul C, Viraben R, Sailler L (2006) Rituximab induced remission of pemphigus vulgaris: 2 cases. Rev Med Interne 28:266\u2013268","journal-title":"Rev Med Interne"},{"key":"8021_CR28","first-page":"266","volume":"16","author":"A Niedermeier","year":"2006","unstructured":"Niedermeier A, Worl P, Barth S, Schuler G, Hertl M (2006) Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 16:266\u2013270","journal-title":"Eur J Dermatol"},{"key":"8021_CR29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2005.08.047","volume":"55","author":"JL McGinness","year":"2006","unstructured":"McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT (2006) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol 55:143\u2013148","journal-title":"J Am Acad Dermatol"},{"key":"8021_CR30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2133.2007.08048.x","volume":"157","author":"E Sadler","year":"2007","unstructured":"Sadler E, Schafleitner B, Lanschuetzer C, Laimer M, Pohla-Gubo G, Hametner R, Hintner H, Bauer JW (2007) Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 157:417\u2013419","journal-title":"Br J Dermatol"},{"key":"8021_CR31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2133.2003.05580.x","volume":"149","author":"M Goebeler","year":"2003","unstructured":"Goebeler M, Herzog S, Br\u00f6cker EB, Zillikens D (2003) Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 149:899\u2013901","journal-title":"Br J Dermatol"},{"key":"8021_CR32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","volume":"153","author":"MP Arin","year":"2005","unstructured":"Arin MP, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620\u2013625","journal-title":"Br J Dermatol"},{"key":"8021_CR33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bmt.1703654","volume":"30","author":"P Szabolcs","year":"2002","unstructured":"Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J (2002) Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 30:327\u2013329","journal-title":"Bone Marrow Transplant"},{"key":"8021_CR34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archderm.142.2.147","volume":"142","author":"E Schmidt","year":"2006","unstructured":"Schmidt E, Benoit S, Br\u00f6cker EB, Zillikens D, Goebeler M (2006) Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142:147\u2013150","journal-title":"Arch Dermatol"},{"key":"8021_CR35","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54:3612\u20133622","journal-title":"Arthritis Rheum"},{"key":"8021_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","volume":"140","author":"A Dupuy","year":"2004","unstructured":"Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H (2004) Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140:91\u201396","journal-title":"Arch Dermatol"},{"key":"8021_CR37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","volume":"153","author":"E Schmidt","year":"2005","unstructured":"Schmidt E, Herzog S, Br\u00f6cker EB, Zillikens D, Goebeler M (2005) Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153:449\u2013451","journal-title":"Br J Dermatol"},{"key":"8021_CR38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741\u2013750","journal-title":"Nat Rev Immunol"},{"key":"8021_CR39","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"8021_CR40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601\u2013607","journal-title":"Arthritis Rheum"},{"key":"8021_CR41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2006.01.041","volume":"148","author":"M Willems","year":"2006","unstructured":"Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623\u2013627","journal-title":"J Pediatr"},{"key":"8021_CR42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","volume":"358","author":"P Quartier","year":"2001","unstructured":"Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511\u20131513","journal-title":"Lancet"},{"key":"8021_CR43","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","volume":"101","author":"M Zecca","year":"2003","unstructured":"Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857\u20133861","journal-title":"Blood"},{"key":"8021_CR44","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ (2006) Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639\u20132642","journal-title":"Blood"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-007-8021-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-007-8021-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T00:33:26Z","timestamp":1684024406000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-007-8021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,4]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["8021"],"URL":"https:\/\/doi.org\/10.1007\/s12016-007-8021-6","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,4]]}}}